Press releases

May 23, 2018

BERG Announces FDA Orphan-Drug Designation of BPM 31510 for the Treatment of Patients with Epidermolysis Bullosa

BERG Announces FDA Orphan-Drug Designation of BPM 31510 for the Treatment of Patients with Epidermolysis Bullosa NEWS PROVIDED BY BERG  May 23, 2018, 07:34 ET SHARE THIS ARTICLE BOSTON, May 23, 2018 /PRNewswire/ — BERG, LLC, a Boston-based biopharmaceutical...

May 23, 2018

BERG Announces FDA Orphan-Drug Designation of BPM 31510 for the Treatment of Patients with Epidermolysis Bullosa

BERG Announces FDA Orphan-Drug Designation of BPM 31510 for the Treatment of Patients with Epidermolysis Bullosa NEWS PROVIDED BY BERG  May 23, 2018, 07:34 ET BOSTON, May 23, 2018 /PRNewswire/ — BERG, LLC, a Boston-based biopharmaceutical company that merges...

April 18, 2018

BERG Announces Data Presentations at AACR 2018 Validating Novel Prostate Cancer Biomarkers and Clinical Activity of BPM 31510 Across Several Metabolic Cancer Types

BERG, a biopharmaceutical company that merges biology with technology to map the nature of diseases, today announced the presentation of 10 abstracts describing progress on translational preclinical data on display at the American Association for Cancer...

April 4, 2018

BERG Announces the Dosing of First UK Patient in Phase II Combination Trial of BPM 31510 and Gemcitabine for Patients with Pancreatic Cancer

BERG, a biopharmaceutical company that merges biology with technology to map the nature of diseases, today announced the dosing of the first patient in the United Kingdom (UK) for its Phase II pancreatic cancer clinical trial...

January 22, 2018

BERG Announces FDA Orphan-Drug Designation of BPM31510 for the Treatment of Pancreatic Cancer

BERG, a Boston-based biopharmaceutical company that merges biology with technology to map the nature of diseases, today announced the U.S. Food and Drug Administration (FDA) has granted orphan-drug designation to the Company’s leading product candidate BPM31510,...

December 13, 2017

New Research Partnership will Leverage BERG’s Interrogative Biology® Platform to Identify Novel Biomarker and Targets for Diagnosis and Treatment of Alzheimer’s Disease

BERG’s Interrogative Biology® Platform will Evaluate Clinically Annotated Biospecimens to Discover Diagnostic Biomarkers and Treatments for Neurological Diseases BOSTON — BERG, a biopharmaceutical company that merges biology with technology to map the nature of diseases, Massachusetts...

October 30, 2017

BERG Enters Into an Agreement With Sanofi Pasteur to Identify Biomarkers of Flu Vaccine Performance

Molecular Data Will be Analyzed Using Artificial Intelligence Through BERG’s Interrogative Biology® Platform to Better Understand Influenza Vaccination Response BOSTON — BERG, a biopharmaceutical company that merges biology with technology, today announced a new research effort...

October 27, 2017

BERG Honored with Partner in Progress Award from DEBRA of America at Annual Benefit for Rare Disease Epidermolysis Bullosa

BERG’s BPM 31510 Drug Candidate Recognized as Potential Novel Therapy for Treating Rare Disease BOSTON — BERG, a biopharmaceutical company that merges biology with technology, today announced that the Company was honored with a Partners in...

October 3, 2017

BERG Broadens Relationship with Department Of Defense (DoD) Center For Prostate Disease Research with New Predictive Biomarker Test for Prostate Cancer

New Clinical Evidence Guided by Artificial Intelligence that Could Significantly Enhance Prostate Cancer Detection and Reduce Over-Diagnosis and Unnecessary Treatments in Benign Prostate Hyperplasia Patients arises from Research Collaboration with BERG and the Center for Prostate...

September 11, 2017

BERG Presents Key Clinical Data at ESMO 2017 on BPM 31510 for Advanced Pancreatic Cancer Patients and BPM 31543 for Preventing Hair-Loss in Patients Treated With Chemotherapy

New Data Show Promising Results and Support Continued Clinical Development,Highlights Success of Interrogative Biology Platform to Advance Potential New Treatment Options for Cancer Patients BOSTON, Sept. 11, 2017 — BERG, a biopharmaceutical company that merges biology with...

August 28, 2017

BERG Forms Research Collaboration with AstraZeneca to Identify New Therapeutic Targets to Treat Neurological Disorders such as Parkinson’s Disease

Collaboration to Focus on a Disease Target in Parkinson’s Disease With Berg’s Interrogative Biology® Technology BOSTON, Aug. 28, 2017 – BERG, a biopharmaceutical company that merges biology with technology to map the nature of diseases, today...

May 15, 2017

BERG Announces New Partnership with debra of America to Tackle Epidermolysis Bullosa, a Rare Genetic Tissue Disorder

Biopharmaceutical and Patient Advocacy Group Join Forces to Galvanize the Disease Community and Advance Treatment Research BOSTON, May 15, 2017 — BERG, a biopharmaceutical company uncovering health solutions through a data-driven, biological research approach, today announced...

April 3, 2017

BERG Announces BPM 31510 Data Presentations at 2017 AACR in Immuno-Oncology, Glioblastoma Multiforme, Pancreatic Cancers and Novel Prostate Cancer Biomarker Panel

BOSTON, April 3, 2017 — BERG, a biopharmaceutical company uncovering health solutions through a data-driven, biological research approach, today announced seven poster presentations showing promising preclinical data. This data reflects the impact of BERG’s leading product...

March 27, 2017

New Data Published in Nature Medicine from Joslin Diabetes Center Demonstrates the Importance of Interrogating Human Biology

BOSTON, March 27, 2017— BERG, a biopharmaceutical company uncovering health solutions through a data-driven, biological research approach, today announced that the company’s Interrogative Biology® Platform contributed to the discovery of new data using a cold-induced model to promote...

February 15, 2017

BERG Initiates Phase I/II Monotherapy Trial of BPM 31510-IV in Patients with Glioblastoma Multiforme (GBM)

BOSTON, Feb. 15, 2017 — BERG LLC, a biopharmaceutical company uncovering health solutions through a data-driven, biological research approach, today announced that it has initiated a Phase I/II monotherapy clinical trial for its drug candidate BPM 31510-IV for...

January 12, 2017

BERG Enters into Multi-Year Agreement with BD for Next-Generation Analytics in Healthcare IT

Leading Health Companies Combine Health IT Expertise to Advance Patient Health Outcomes BOSTON, Jan. 12, 2017 — BERG, a biopharmaceutical company uncovering health solutions through a data-driven, biological research approach, announced a multi-year agreement between BERG Analytics, a...

November 14, 2016

BERG Presents Data Uncovering a Novel Contributor to Parkinson’s Disease at Society for Neuroscience 2016 Meeting

BERG Presents Data Uncovering a Novel Contributor to Parkinson’s Disease at Society for Neuroscience 2016 Meeting BERG Interrogative Biology® Platform Identifies Potential Contributor to LRRK2-mediated Cell Death in Parkinson’s Disease BOSTON, November 14, 2016 — BERG, a biopharmaceutical...

November 1, 2016

BERG, The Icahn School of Medicine at Mount Sinai to host “Fast Track” event at Fast Company’s Second Annual Innovation Festival 2016

BERG, The Icahn School of Medicine at Mount Sinai to host “Fast Track” event at Fast Company’s Second Annual Innovation Festival 2016 Leading players at the forefront of healthcare innovation will discuss how emerging technologies are...

August 17, 2016

BERG Strengthens Financial Leadership And Expands Board Of Directors

BOSTON, Aug. 17, 2016 /PRNewswire/ — BERG, a technology-based biopharmaceutical company uncovering health solutions through a data-driven, systems biological research approach, today announced an expansion of its Board of Directors, adding three new members who bring a...

June 5, 2016

BERG Announces Clinical Trial Data Presentations Of BPM 31510 In Advanced Solid Tumors And BPM 31543 For Prevention Of Chemotherapy-Induced Alopecia At American Society of Clinical Oncology Annual Meeting

BOSTON, June 5, 2016 /PRNewswire/ — BERG, a biopharmaceutical company uncovering health solutions through a data-driven, biological research approach, today announced that it will present two poster presentations on the Phase 1 study of BPM 31510...

April 27, 2016

BERG Initiates Phase II Combination Trial Of BPM 31510 And Gemcitabine In Patients With Pancreatic Cancer

BOSTON, April 27, 2016 /PRNewswire/ — BERG, a biopharmaceutical company uncovering health solutions through a data-driven, biological research approach, today announced that it has initiated a Phase II clinical trial for its drug candidate BPM 31510 in...

BERG in the News!

BERG is making headlines.  Click here to see the latest breaking news, interviews, and press releases.